Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Syntocinon for Social Impairment in High Functioning ASD
NCT02985749Phase 3Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2017
- Primary completion
- Jan 2019
- Countries
- 1
01
Overview
Phase 3, open-label trial of oxytocin nasal spray in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Social Responsiveness Scale 2 at 8 weeks. Started Oct 2017; status: completed.
02
Drugs
oxytocin nasal spray
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT02985749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02985749.